{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:37:40Z","timestamp":1781717860913,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ajt.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T17:28:58Z","timestamp":1728494938000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-3381","authenticated-orcid":false,"given":"Sindhu","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-4680","authenticated-orcid":false,"given":"Flavio","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib1","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2024.10.005_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2215\/CJN.05321107","article-title":"Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies","volume":"3","author":"Akalin","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13751","article-title":"Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: is there still a role for desensitization?","volume":"33","author":"Schinstock","year":"2019","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2024.10.005_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/TP.0b013e3182590d2e","article-title":"Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients","volume":"94","author":"Marfo","year":"2012","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.ajt.2024.10.005_bib6","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2024.10.005_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101465","article-title":"BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization","volume":"69","author":"Agarwal","year":"2021","journal-title":"Transpl Immunol"},{"issue":"1","key":"10.1016\/j.ajt.2024.10.005_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ajt.16709","article-title":"Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates","volume":"22","author":"Jouve","year":"2022","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2024.10.005_bib9","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","article-title":"Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes)","volume":"105","author":"Jordan","year":"2021","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ajt.2022.11.001","article-title":"Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy","volume":"23","author":"Hill","year":"2023","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2024.10.005_bib11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","article-title":"32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody","volume":"101","author":"Moreno Gonzales","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ajt.15613","article-title":"A\u00a0prospective, iterative, adaptive trial of carfilzomib-based desensitization","volume":"20","author":"Tremblay","year":"2020","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2024.10.005_bib13","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib14","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A\u00a0randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2024.10.005_bib16","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/ajt.16391","article-title":"Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?","volume":"21","author":"Massat","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A\u00a0randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"Suppl 4","key":"10.1016\/j.ajt.2024.10.005_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ajt.15873","article-title":"Experimental modeling of desensitization: what have we learned about preventing AMR?","volume":"20","author":"Kwun","year":"2020","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2024.10.005_bib19","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/ajt.13761","article-title":"Delayed cytotoxic T lymphocyte-associated protein 4-immunoglobulin treatment reverses ongoing alloantibody responses and rescues allografts from acute rejection","volume":"16","author":"Young","year":"2016","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2024.10.005_bib20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2016070727","article-title":"Humoral compensation after bortezomib treatment of allosensitized recipients","volume":"28","author":"Kwun","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ajt.2024.10.005_bib21","first-page":"99","article-title":"CD38\/CD31, a receptor\/ligand system ruling adhesion and signaling in human leukocytes","volume":"75","author":"Deaglio","year":"2000","journal-title":"Chem Immunol"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib22","first-page":"81","article-title":"Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues","volume":"12","author":"Fern\u00e0ndez","year":"1998","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ajt.2024.10.005_bib24","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ajt.2024.10.005_bib25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ajt.2024.10.005_bib26","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/TP.0000000000004719","article-title":"New desensitization strategy: daratumumab for highly sensitized pediatric heart transplant candidate","volume":"107","author":"Baez Hernandez","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ajt.2024.10.005_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11771","article-title":"A\u00a0novel daratumumab-based regimen for desensitization in highly HLA-presensitized patients awaiting kidney transplantation","volume":"36","author":"Zhao","year":"2023","journal-title":"Transpl Int."},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ajt.2024.10.005_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajt.2024.08.004","article-title":"Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates","volume":"25","author":"Torija","year":"2025","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2024.10.005_bib30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.15881","article-title":"Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients","volume":"20","author":"Jain","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2024.10.005_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ajt.12526","article-title":"Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection","volume":"14","author":"Kim","year":"2014","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib33","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1111\/ajt.16113","article-title":"Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition","volume":"20","author":"Alishetti","year":"2020","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib34","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: is it time to target the real culprit?","volume":"23","author":"de Nattes","year":"2023","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2024.10.005_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/tan.15458","article-title":"Daratumumab treatment in six highly sensitised solid organ transplant recipients: a case series and literature review","volume":"103","author":"Lemal","year":"2024","journal-title":"HLA"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2024.10.005_bib38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.healun.2022.06.017","article-title":"Daratumumab provides transient response of antibody mediated rejection post pediatric orthotopic heart transplantation","volume":"41","author":"Fenton","year":"2022","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A\u00a0randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ajt.2024.10.005_bib40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med."},{"issue":"5","key":"10.1016\/j.ajt.2024.10.005_bib41","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.ajt.2024.10.005_bib43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2024.10.005_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ajt.2024.10.005_bib45","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/bloodadvances.2019001091","article-title":"Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses","volume":"4","author":"Manna","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ajt.2024.10.005_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.ajt.2024.10.005_bib47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","article-title":"Daratumumab use prior to kidney transplant and T cell-mediated rejection: a case report","volume":"81","author":"Scalzo","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.ajt.2024.10.005_bib48","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"issue":"20","key":"10.1016\/j.ajt.2024.10.005_bib49","article-title":"Daratumumab interferes with allogeneic crossmatch impacting immunological assessment in solid organ transplantation","volume":"11","author":"Ho","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.ajt.2024.10.005_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524006336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524006336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:00:34Z","timestamp":1736809234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613524006336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1600613524006336"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2024.10.005","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}